The potent and selective TNKS1/2 inhibitor G007‐LK significantly inhibited Wnt/β‐catenin signaling in models of colorectal cancer, showing therapeutic efficacy in Wnt/β‐catenin pathway mutation‐driven colorectal cancer. The gene discussed is TNKS; the disease is colorectal cancer.